Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiragolumab - Genentech

Next Previous
Drug Profile

Tiragolumab - Genentech

Alternative Names: anti-TIGIT - Roche; MTIG-7192A; RG-6058; RG6058-10; RG6058-11; RO 7092284

Latest Information Update: 09 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; National Cancer Institute (USA); Roche; Washington University School of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued B-cell lymphoma; Cervical cancer; Gastric cancer; Liver cancer; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Rectal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer

Most Recent Events

  • 31 Jul 2025 Roche completes the phase III trial in Small cell lung cancer (Combination therapy, First-line therapy) in Australia, Austria, Belgium, Brazil, China, Czech Republic, Germany, Greece, Hungary, Italy, Japan, Multinational, Netherlands, New Zealand, Poland, Russia, Scotland, Serbia, Singapore, South Korea, Spain, Switzerland, Taiwan, Turkey, United Kingdom and USA (IV, Infusion) (NCT04256421)
  • 31 Jul 2025 Roche completes a phase III SKYSCRAPER-03 trial for Non-small cell lung cancer (Late-stage disease, Combination therapy, Metastatic disease, Second-line therapy or greater, Unresectable) in US, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, South Korea, Netherlands, New Zealand, Poland, Portugal, Spain, Taiwan, Thailand, Turkey and United Kingdom (IV) (NCT04513925) (EudraCT2019-004773-29)
  • 24 Jul 2025 Discontinued - Phase-I/II for Liver cancer (First-line therapy, Combination therapy, Metastatic disease, Late-stage disease) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top